Antimicrobial shortages are monitored by the ADSP team and if adjustments to prescribing are needed, this page will be updated.
Oseltamivir Use December 1, 2022
Oseltamivir (Tamiflu) for the treatment of influenza supply is adequate at this time, but future resupply may be unreliable. Outpatient availability varies and depends on retail pharmacy supply. At this time, clinicians can continue to prescribe as usual although patients may not be able to obtain it at their usual retail pharmacy and may have to utilize an alternative pharmacy.
In concordance with CDC Recommendations for the treatment of influenza and to avoid unnecessary utilization, please refer to the following guidance for optimal inpatient or observation Oseltamivir use:
Initiation of oseltamivir treatment for patients admitted to an NM hospital will be restricted to patients with respiratory infections consistent with influenza.
Oseltamivir for these patients should be started as soon as possible after presentation. It should be initiated concurrently with rapid influenza PCR testing.
If the Influenza PCR test is negative, oseltamivir must be discontinued unless authorized through Infectious Diseases consultation.
For patients who test influenza positive, a full 5-day course of oseltamivir will be initiated.
For all but ICU level of care patients, therapy courses beyond 5 days will not be allowed without an Infectious Diseases consultation.
Oseltamivir dosing for the treatment of influenza:
CrCL: Dose
≥ 60 mL/min: 75 mg BID
>30 to 60 mL/min: 75 mg x1, then 30mg BID
>10 to 30 mL/min: 30 mg daily
≤ 10 mL/min, anephric: 30 mg q48h
Hemodialysis: 30 mg x1, then 30mg 3x weekly post-HD
If only 75mg capsules are available (historical oseltamivir dosing for the treatment of influenza):
